Original Article
Maintenance Treatment of Major Depression in Old Age
N Engl J Med 2006; 354:1130-1138March 16, 2006DOI: 10.1056/NEJMoa052619
- Abstract
Background
Elderly patients with major depression, including those having a first episode, are at high risk for recurrence of depression, disability, and death.
Methods
We tested the efficacy of maintenance paroxetine and monthly interpersonal psychotherapy in patients 70 years of age or older who had depression (55 percent of whom were having a first episode) in a 2-by-2, randomized, double-blind, placebo-controlled trial. Among patients with a response to treatment with paroxetine and psychotherapy, 116 were randomly assigned to one of four maintenance-treatment programs (either paroxetine or placebo combined with either monthly psychotherapy or clinical-management sessions) for two years or until the recurrence of major depression. Clinical-management sessions, conducted by the same nurses, social workers, and psychologists who provided psychotherapy, involved discussion of symptoms.
Results
Major depression recurred within two years in 35 percent of the patients receiving paroxetine and psychotherapy, 37 percent of those receiving paroxetine and clinical-management sessions, 68 percent of those receiving placebo and psychotherapy, and 58 percent of those receiving placebo and clinical-management sessions (P=0.02). After adjustment for the effect of psychotherapy, the relative risk of recurrence among those receiving placebo was 2.4 times (95 percent confidence interval, 1.4 to 4.2) that among those receiving paroxetine. The number of patients needed to be treated with paroxetine to prevent one recurrence was 4 (95 percent confidence interval, 2.3 to 10.9). Patients with fewer and less severe coexisting medical conditions (such as hypertension or cardiac disease) received greater benefit from paroxetine (P=0.03 for the interaction between treatment with paroxetine and baseline severity of medical illness).
Conclusions
Patients 70 years of age or older with major depression who had a response to initial treatment with paroxetine and psychotherapy were less likely to have recurrent depression if they received two years of maintenance therapy with paroxetine. Monthly maintenance psychotherapy did not prevent recurrent depression. (ClinicalTrials.gov number, NCT00178100.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Time from Randomization to Recurrence.Article Activity
- Article
Depression has a strong tendency to recur in elderly persons, with rates of recurrence of 50 to 90 percent over a period of two to three years1; hence, the goal of treatment is not only recovery but also the prevention of recurrence.2 Finding practical and affordable depression-management strategies that prevent recurrence is of great importance.3-6
There are few data from controlled studies on the efficacy of maintenance antidepressant medication or depression-specific psychotherapy in patients 70 years of age or older. We have reported that maintenance nortriptyline, monthly interpersonal psychotherapy, and the two in combination7 are superior to placebo plus clinical-management sessions in preventing recurrences among patients 59 years of age or older who have had multiple episodes.8 Selective serotonin-reuptake inhibitors (SSRIs) have now become the first-line treatment for depression in the elderly because of their favorable side-effect profiles and low risk of complications after an overdose.9 However, there is little information about the long-term efficacy of SSRIs or psychotherapy in the elderly, and the available data are conflicting.10,11 There is also no consensus about whether long-term maintenance pharmacotherapy is appropriate after a first episode of depression; most experts support the use of only 6 to 12 months of continued treatment for patients who have a first episode of depression in old age.9
We assessed whether long-term antidepressant treatment would affect the recurrence of depression specifically in people 70 years of age or older, the majority of whom were having a first episode of depression, since this population is at high risk for recurrence, cognitive impairment, intercurrent medical illness, and suicide.2
Methods
The study setting was a university-based clinic for the treatment of depression in elderly patients. The study was conducted after approval from the university's institutional review board. Between March 1, 1999, and February 28, 2003, we recruited 210 patients, 195 of whom started short-term treatment (Table 1Table 1
Baseline Demographic and Clinical Characteristics of the Patients.). The patients were at least 70 years of age; met the criteria of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV),12 for current major depression (nonpsychotic and nonbipolar), as determined according to the Structured Clinical Interview for DSM-IV Axis I Disorders, version 2.013; and had a score of at least 15 on the 17-item Hamilton Rating Scale for Depression14 (scores can range from 0 to 52, with higher scores indicating more severe depression) and at least 17 on the Folstein Mini–Mental State Examination15 (scores can range from 0 to 30, with higher scores indicating better mental status). All patients provided written informed consent.We screened 363 patients, 153 of whom were excluded and 210 of whom agreed to participate (Figure 1Figure 1
Enrollment and Outcomes.). Of the 195 who began short-term treatment, 151 (77.4 percent) had a clinical response (i.e., a Hamilton score of 0 to 10 for 3 consecutive weeks) and began 16 weeks of continued treatment, which was intended to stabilize and further improve the clinical response. Of these 151 patients, 116 (76.8 percent) remained well and were randomly assigned to a two-year maintenance-treatment program.During short-term treatment, 10 of 195 patients (5.1 percent) were withdrawn from the trial: 3 because of hyponatremia, 2 because of rash, and 1 each because of nausea, orthostasis, unsteady gait, confusion, and paresthesias. During continued treatment, 5 of 151 patients (3.3 percent) were withdrawn from the trial: 2 because of sexual dysfunction, 1 because of tremors, and 2 because of gastrointestinal symptoms. Two patients, both with preexisting cardiac disease, died after myocardial infarction (one each during short-term and continued treatment). No patient committed suicide.
The patients received open treatment with paroxetine and weekly psychotherapy; the dose of paroxetine was initially 10 mg per day and was titrated over an eight-week period to a maximum of 40 mg per day. After having a response, the patients began 16 weeks of open continued treatment consisting of paroxetine and psychotherapy, with paroxetine continued at the same dose but with the frequency of psychotherapy decreasing to once every 2 weeks. As detailed elsewhere,16,17 69 patients received augmented pharmacotherapy with bupropion, nortriptyline, or lithium. If successful, augmented pharmacotherapy was continued for the remainder of a patient's participation unless he or she was randomly assigned to placebo during maintenance therapy. Thirty-eight of the 69 patients receiving augmented pharmacotherapy participated in the maintenance phase of the study, with 19 randomly assigned to paroxetine and 19 to placebo.
Patients who made a full or a partial recovery were randomly assigned to one of four maintenance treatments: paroxetine plus monthly clinical-management sessions, placebo plus monthly clinical-management sessions, paroxetine plus monthly psychotherapy, and placebo plus monthly psychotherapy. The paroxetine, placebo, and augmented-pharmacotherapy tablets were identical in size, weight, and appearance. For patients assigned to maintenance placebo, the paroxetine dose was slowly tapered (together with the dose of any augmented pharmacotherapy) over a period of six weeks under double-blind conditions until discontinuation of the medication. The patients continued to receive maintenance therapy for two years or until recurrence of major depression. At the time of data analysis, four patients were still receiving maintenance therapy and had not yet completed two years of therapy; data from these patients were treated as censored observations.
The randomization schedule was generated by a project statistician at the beginning of the trial. Randomization was stratified according to the number of episodes (single vs. multiple), use of augmented pharmacotherapy, and level of cognitive impairment (a score of more than 130 vs. a score of 130 or less on the Mattis Dementia Rating Scale [scores can range from 0 to 144, with higher scores indicating better cognitive function]). Randomization was blocked to adjust cell sizes over the study period. The treatment team and outcome assessors were unaware of the patients' treatment assignments, and only the research pharmacist and the open-monitoring committee knew which patients were assigned to paroxetine and which to placebo.
The patients were seen monthly by the same clinician (a nurse, social worker, or psychologist) who had treated them during short-term and continued treatment. Patients assigned to clinical management were seen for 30-minute visits; they received no specific psychotherapy but were asked about symptoms and any possible adverse effects. The same clinicians conducted clinical-management sessions and psychotherapy. At each visit, orthostatic blood pressure and pulse were measured, body weight was recorded, and clinical ratings were performed with the use of the Hamilton Rating Scale for Depression.17 Patients assigned to monthly psychotherapy were seen for 45-minute sessions. In order to ensure fidelity to manual-based treatment-delivery procedures, all clinical-management and psychotherapy sessions were audiotaped so that elements specific to interpersonal psychotherapy and to medical management could be rated in a blinded fashion.18 The clinicians encouraged and monitored adherence by education of patients and family members, pill counts, and reminders at each clinic visit.
Recurrence of a major depressive episode, as defined by DSM-IV criteria and a Hamilton score of at least 15, was determined by administration of the Structured Clinical Interview for DSM-IV Axis I Disorders, version 2.0,13 and independently confirmed clinically by a geriatric psychiatrist. Assessment of possible recurrence was performed as needed at any point during maintenance treatment. Both assessors were unaware of patients' treatment assignments. GlaxoSmithKline provided paroxetine tablets for use in this research study but had no other role in study design, data accrual, or data analysis.
Statistical Analysis
We estimated that the enrollment of 33 patients per active-treatment group and 20 patients in the placebo group (total, 119) would provide the study with a statistical power of at least 80 percent (α=0.05) to detect a difference in recurrence rates of 60 percent between combined therapy and placebo and of 30 percent between each monotherapy and placebo. We assigned fewer patients to the placebo group because we hypothesized that the recurrence rate would be higher among patients receiving placebo and we wanted to maximize the number of observations in the active-treatment groups to test for pairwise differences in recurrence rates.
Our study hypothesis was that the four groups would differ from one another, and that the specific pattern of group differences would demonstrate the superiority of combined treatment (paroxetine plus interpersonal therapy) over each of the other three treatments and of either monotherapy over placebo plus clinical management. First, we used Kaplan–Meier survival analysis with log-rank chi-square statistics to test for overall differences in recurrence rates among the four maintenance treatments. We examined the survival curves stratified according to the number of episodes of major depression, level of cognitive impairment, and use of augmented pharmacotherapy. Second, to perform hypothesized pairwise contrasts, we used Cox proportional-hazards models with three dummy variables representing the four treatment groups. The Cox models tested for the effects of clinically relevant covariates on recurrence: the number and severity of concomitant medical illnesses (the “chronic medical burden”), as defined by scores for the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)19 (range, 0 to 52, with higher scores indicating worse health status); anxiety, as defined by scores for the Brief Symptom Inventory Anxiety subscale20 (range, 0 to 3, with higher scores indicating worse condition); cognitive impairment, as defined by scores for the Mattis Dementia Rating Scale21; and subjective sleep quality, as defined by scores for the Pittsburgh Sleep Quality Index22 (range, 0 to 21, with higher scores indicating a poorer quality of sleep). We also used Cox models to test for moderation of maintenance-treatment effects on recurrence, as evidenced by interaction of treatment with each clinical covariate.
Results
The four maintenance groups had similar demographic and clinical characteristics (Table 1). The time from randomization to recurrence of depression (Figure 2Figure 2
Time from Randomization to Recurrence.) differed among the four groups (P=0.02). The actuarial recurrence rates (after adjustment for censoring) were 35 percent among patients receiving paroxetine plus psychotherapy, 37 percent among those receiving paroxetine plus clinical-management sessions, 68 percent among those receiving placebo plus psychotherapy, and 58 percent among those receiving placebo plus clinical-management sessions. The Cochran–Mantel–Haenszel statistic for recurrence across the four groups stratified according to the receipt of augmented pharmacotherapy was also significant (P=0.03). The recurrence rates were higher among those who had received augmented pharmacotherapy (74 percent) than among those who had not (29 percent, P<0.001).A sensitivity analysis treating the four patients who had not yet completed two years of treatment at the time of the data analysis as having either completed the study without recurrence or as having had a recurrence of depression at the time of censoring yielded similar results to those shown in Figure 2 (P=0.02 and P=0.04, respectively).
Testing of hypothesized pairwise contrasts indicated that paroxetine plus psychotherapy was superior to placebo plus psychotherapy (P=0.03) and to placebo plus clinical management (P=0.05) in preventing recurrence. Similarly, paroxetine plus clinical management (without psychotherapy) was significantly more effective than placebo plus psychotherapy (P=0.03) and marginally more effective than placebo plus clinical management (P=0.06).
When recurrence outcomes among patients treated with paroxetine were compared with those among patients receiving placebo, after adjustment for psychotherapy status, the number of patients who needed to be treated with paroxetine to prevent one recurrence was 4 (95 percent confidence interval, 2.3 to 10.9). The relative risk of recurrence among patients receiving placebo was 2.4, as compared with those receiving paroxetine (95 percent confidence interval, 1.4 to 4.2).
In the subgroup of 69 patients enrolled during their first episode of depression, the recurrence rate among those receiving paroxetine (with or without psychotherapy) was 27 percent, as compared with 56 percent among those receiving placebo (with or without psychotherapy) (P=0.003). The recurrence rate among the 47 patients enrolled during a second or later episode of depression was 38 percent among those receiving paroxetine (with or without psychotherapy), as compared with 62 percent among those receiving placebo (with or without psychotherapy); the difference between the rates was not significant (P=0.22).
In Cox models, more severe anxiety (P=0.04), more numerous and more severe concomitant medical illnesses (P=0.02), and poorer sleep quality (P=0.001) all predicted a shorter period without depression. A significant interaction between the medical burden (as measured by the CIRS-G score) and drug assignment (P=0.03) indicated a moderating effect of the number and severity of coexisting medical illnesses on the long-term outcome. The hazard ratio for the interaction between drug assignment and CIRS-G score was 1.17 (95 percent confidence interval, 1.02 to 1.35), a value consistent with the presence of a small effect. (No moderation effect was found for cognition, anxiety, or sleep.) To illustrate the interaction of the number and severity of concomitant medical illnesses with pharmacotherapy, we dichotomized the CIRS-G scores at a mean value of 10 (Figure 3Figure 3
Effect of the Number and Severity of Concomitant Medical Illnesses on the Efficacy of Maintenance Therapy with Paroxetine.); the results showed that patients with fewer and less severe concomitant medical illnesses fared better during paroxetine maintenance therapy than those with more numerous and more severe concomitant medical illnesses.Discussion
Our data provide support for the use of maintenance SSRI pharmacotherapy, but not interpersonal psychotherapy, to prevent recurrent depression in people 70 years of age or older, including those with a first episode of depression. To date, there has been no consensus about the appropriateness of long-term maintenance treatment for a first episode of depression in elderly patients, with most experts calling for only 6 to 12 months of continued treatment.9
We identified 10 published double-blind, placebo-controlled, maintenance trials of SSRIs and other nontricyclic antidepressants in adult patients,23-32 but only 2 studies among patients 65 years of age or older.10,11 All 10 studies in adults had positive findings, but the results of studies in elderly patients were mixed. Klysner et al.10 demonstrated the maintenance efficacy of citalopram, whereas Wilson et al.11 failed to find a difference between sertraline and placebo. In the study by Klysner et al., 85 percent of 121 participants (mean age, 74 to 75 years) were having their first episode of major depression. Among the 60 patients randomly assigned to citalopram, 19 (32 percent) had a recurrence during the 48-week maintenance-treatment period, as compared with 41 of the 61 patients receiving placebo (67 percent). Our data from patients receiving paroxetine replicate these findings and extend them to patients receiving two years of maintenance treatment, thereby adding substantially to the body of knowledge regarding long-term treatment strategies in elderly depressed people, especially those with a single episode of major depression. To place our observation within a broader medical context, the number of patients needed to be treated with paroxetine for two years to prevent a recurrence of depression is 4; in comparison, four large trials33 of statins, which are widely used for the prevention of a second myocardial infarction, found that the number of patients needed to be treated with statins for five years to prevent another myocardial infarction was 21.
Our results are also noteworthy because few data from controlled studies provide support for the short-term efficacy of SSRIs in late-life depression. Only two published randomized, controlled trials of any SSRI in older adults, both of which used fluoxetine, are included in the Cochrane Database of Systematic Reviews (most recent update, February 25, 2005).34 For short-term treatment, the pooled results give a number needed to treat of 8.5. In a large, eight-week, placebo-controlled trial of sertraline in the elderly, the adjusted mean difference between groups in scores on the Hamilton Rating Scale for Depression was only 1.5 points at the end of the study.35 The only other published study of short-term SSRI treatment, a multisite, placebo-controlled trial of citalopram,36 failed to demonstrate short-term efficacy in patients 75 years of age or older. In contrast to studies of short-term efficacy, our study supports the efficacy of maintenance therapy with SSRIs in preventing a recurrence of depression among people with first episodes in later life who have apparently benefited from initial SSRI treatment and interpersonal psychotherapy.
Contrary to our hypothesis, the current data failed to provide support for the efficacy of maintenance psychotherapy, despite the fact that we had sufficient power to detect a clinically significant effect. The failure to demonstrate the efficacy of psychotherapy in the prevention of recurrence among patients 70 years of age or older could reflect differences between the patients in the current study and those in our earlier study,8 since the psychotherapists who treated the patients were largely the same in both studies. The patients in the current study were, on average, 10 years older than those in the previous study (77 vs. 67 years) and had more cognitive impairment and coexisting medical illnesses. The results stand in contrast to those of previous studies that have demonstrated moderate prophylactic effects of psychotherapy in nongeriatric adults37 and in the “young” elderly (mainly 60 to 75 years of age).8 The patients in both previous studies had recurrent major depression, whereas the majority of patients in the current study had late-onset first episodes of depression. Late-onset depression occurs in a heterogeneous group of patients, some of whom may be in the preclinical stages of Alzheimer's disease or vascular dementia.38 Their ability to learn and to modify their behavior (executive function) may be compromised; hence, psychotherapy for such patients may need to involve caregivers more extensively. More research is needed to address this issue as well as the use of other types of psychotherapy — such as problem-solving therapy — for such patients.39 Moreover, all patients in the maintenance phase of our study had received psychotherapy during short-term treatment. The recurrence rates might have been higher among patients receiving maintenance SSRI therapy who were not initially treated with psychotherapy.
Given that the number and severity of concomitant medical illnesses (especially hypertension, coronary artery disease, diabetes, hyperlipidemia, osteoarthritis, and chronic lung disease) also affected the risk of recurrence and exerted a slight moderating effect on the response to long-term antidepressant treatment, it is clinically appropriate to link and integrate long-term disease-management strategies for both depression and other coexisting medical illnesses in elderly persons. Since most older people are treated for depression in the general medical sector, integrating and appropriately reimbursing long-term disease management for both depression and other coexisting medical disorders are important. Recent studies have demonstrated the effectiveness of strategies for short-term and continued treatment of depression in elderly patients in primary care settings.3,4,6 Our data indicate that such strategies should be extended to encompass long-term maintenance treatment to prevent recurrence.
In summary, we evaluated both pharmacologic and psychotherapeutic strategies for preventing recurrence of major depression in patients 70 years of age or older and demonstrated that two years of maintenance treatment with paroxetine is effective. This observation can inform long-term disease-management strategies for the treatment of elderly patients with depression in general medical settings.
Supported by grants (P30 MH52247, P30 MH071944, R37 MH43832, and R01 MH37869, to Dr. Reynolds; K24 MH65416, to Dr. Pollock; P30 MH30915, to Dr. Kupfer; K01 MH01684, to Dr. Butters; and K01 MH01613, to Dr. Mulsant) from the National Institute of Mental Health and a grant (P60 MD000207) from the National Center for Minority Health and Health Disparities. GlaxoSmithKline provided the paroxetine tablets.
Dr. Pollock reports having served as a member of the Paxil–Controlled-Release National Psychiatry Advisory Board and having received support from GlaxoSmithKline for laboratory research not connected with the research described in this article. Dr. Mulsant reports having received honoraria from GlaxoSmithKline. No other conflict of interest relevant to this article was reported.
We are indebted to the staff of the Clinical Trials Management Unit in the Advanced Center for Intervention and Services Research for Late-Life Mood Disorders for their help in recruiting, assessing, and treating patients in this study, and to Katherine Slomka, Karen Callas, and Sally Lagattuta for administrative assistance.
Source Information
From the Advanced Center for Intervention and Services Research for Late-Life Mood Disorders and the John A. Hartford Center of Excellence in Geriatric Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic (C.F.R., M.A.D., B.G.P., E.F., M.D.M., P.R.H., M.A.B., J.A.S., M.A.S., E.M.W., A.G., J.K., E.L., K.S., S.B., D.J.K.); the Geriatric Research, Education, and Clinical Center, Pittsburgh Veterans Affairs Health Care System (B.H.M.); and the Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh (S.M.) — all in Pittsburgh.
Address reprint requests to Dr. Reynolds at the Western Psychiatric Institute and Clinic, 3811 O'Hara St., Rm. E-1135, Pittsburgh, PA 15213, or at reynoldscf@upmc.edu.
- References
References
1
Zis AP ,Grof P ,Webster M ,Goodwin FK . Predictors of relapse in recurrent affective disorder. Psychopharmacol Bull 1980;16:47-49
Medline2
Charney DS ,Reynolds CF III ,Lewis L , et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003;60:664-672
CrossRef | Web of Science | Medline3
Dietrich AJ ,Oxman TE ,Williams JW Jr , et al. Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial. BMJ 2004;329:602-602
CrossRef | Web of Science | Medline4
Bruce ML ,Ten Have TR ,Reynolds CF , et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004;291:1081-1091
CrossRef | Web of Science | Medline5
Unutzer J ,Patrick DL ,Simon G , et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study. JAMA 1997;277:1618-1623
CrossRef | Web of Science | Medline6
Unutzer J ,Katon W ,Callahan CM , et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002;288:2836-2845
CrossRef | Web of Science | Medline7
Klerman GL, Weissman MM, Rounsaville BJ, Chevron E. Interpersonal psychotherapy of depression. New York: Basic Books, 1984.
8
Reynolds CF III ,Frank E ,Perel JM , et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999;281:39-45
CrossRef | Web of Science | Medline9
Alexopoulos GS ,Katz IR ,Reynolds CF III ,Carpenter D ,Docherty JP ,Ross RW . Pharmacotherapy of depressive disorders in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract 2001;7:361-376
CrossRef | Medline10
Klysner R ,Bent-Hansen J ,Hansen HL , et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;19:29-35
CrossRef | Web of Science11
Wilson KC ,Mottram PG ,Ashworth L ,Abou-Saleh MT . Older community residents with depression: long-term treatment with sertraline: randomised, double-blind, placebo-controlled study. Br J Psychiatry 2003;182:492-497
CrossRef | Web of Science | Medline12
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 2000.
13
First M, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), version 2.0. New York: New York State Psychiatric Institute, 1995.
14
Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
CrossRef | Web of Science | Medline15
Folstein MF ,Folstein SW ,McHugh PR . “Mini-mental state“: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
CrossRef | Web of Science | Medline16
Whyte EM ,Basinski J ,Farhi P , et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1634-1641
CrossRef | Web of Science | Medline17
Driscoll HC ,Basinski J ,Mulsant BH , et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005;20:661-667
CrossRef | Web of Science | Medline18
Wagner EF ,Frank E ,Steiner SC . Discriminating maintenance treatments for recurrent depression: development and implementation of a rating scale. J Psychother Pract Res 1992;22:281-29119
Miller MD ,Paradis CF ,Houck PR , et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248
CrossRef | Web of Science | Medline20
Derogatis LR ,Melisaratos N . The Brief Symptom Inventory: an introductory report. Psychol Med 1983;13:595-605
CrossRef | Web of Science | Medline21
Mattis S. Dementia Rating Scale (DRS). Odessa, Fla.: Psychological Assessment Resources, 1988.
22
Buysse DJ ,Reynolds CF III ,Monk TH ,Berman SR ,Kupfer DJ . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
CrossRef | Web of Science | Medline23
Keller MB ,Kocsis JH ,Thase ME , et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998;280:1665-1672
CrossRef | Web of Science | Medline24
Lepine JP ,Caillard V ,Bisserbe JC ,Troy S ,Hotton JM ,Boyer P . A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004;161:836-842[Erratum, Am J Psychiatry 2004;161:1320.]
CrossRef | Web of Science | Medline25
Rapaport MH ,Bose A ,Zheng H . Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-49
CrossRef | Web of Science | Medline26
Gelenberg AJ ,Trivedi MH ,Rush AJ , et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003;54:806-817
CrossRef | Web of Science | Medline27
Weihs KL ,Houser TL ,Batey SR , et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002;51:753-761
CrossRef | Web of Science | Medline28
Terra JL ,Montgomery SA . Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:55-62
CrossRef | Web of Science | Medline29
Entsuah AR ,Rudolph RL ,Hackett D ,Miska S . Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-145
CrossRef | Web of Science | Medline30
Gilaberte I ,Montejo AL ,de la Gandara J , et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001;21:417-424
CrossRef | Web of Science | Medline31
Hochstrasser B ,Isaksen PM ,Koponen H , et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-310
CrossRef | Web of Science | Medline32
Feiger AD ,Bielski RJ ,Bremner J , et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:19-28
CrossRef | Web of Science | Medline33
Therapeutics Initiative. Evidence based drug therapy: do statins have a role in primary prevention? (Accessed February 17, 2006, at http://www.ti.ubc.ca/PDF/48.pdf.)
34
Wilson K ,Mottram P ,Sivanranthan A ,Nightingale A . Antidepressant versus placebo for depressed elderly. Cochrane Database Syst Rev 2001;2:CD000561-CD000561
Medline35
Schneider LS ,Nelson JC ,Clary CM , et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160:1277-1285
CrossRef | Web of Science | Medline36
Roose SP ,Sackeim HA ,Krishnan KR , et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004;161:2050-2059
CrossRef | Web of Science | Medline37
Frank E ,Kupfer DJ ,Perel JM , et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099
Web of Science | Medline38
Alexopoulos GS ,Meyers BS ,Young RC , et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000;57:285-290
CrossRef | Web of Science | Medline39
Arean PA ,Reynolds CF III . The impact of psychosocial factors on late-life depression. Biol Psychiatry 2005;58:277-282
CrossRef | Web of Science | Medline
- Citing Articles (127)
Citing Articles
1
A. J. Rothschild. (2013) Challenges in the Treatment of Major Depressive Disorder With Psychotic Features. Schizophrenia Bulletin 39:4, 787-796
2
G. S. Malhi, R. Hitching, M. Berk, P. Boyce, R. Porter, K. Fritz. (2013) Pharmacological management of unipolar depression. Acta Psychiatrica Scandinavica 127, 6-23
3
David J. Kolko, Oliver Lindhiem, Jonathan Hart, Oscar G. Bukstein. (2013) Evaluation of a Booster Intervention Three Years After Acute Treatment for Early-Onset Disruptive Behavior Disorders. Journal of Abnormal Child Psychology
4
C. Wächtler. (2013) Psychotherapie der Altersdepression. Zeitschrift für Gerontologie und Geriatrie 46:2, 120-126
5
Donovan T. Maust, David W. Oslin, Michael E. Thase. (2013) Going Beyond Antidepressant Monotherapy for Incomplete Response in Nonpsychotic Late-Life Depression: A Critical Review. The American Journal of Geriatric Psychiatry
6
Philip Wilkinson, Zehanah Izmeth, Philip Wilkinson. Continuation and maintenance treatments for depression in older people. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
7
Talia Weiss, Mark Weinberger, Arielle M. Schwerd, Jimmie Holland. (2012) A 30-Year Perspective on Psychosocial Issues in Lung Cancer. Thoracic Surgery Clinics 22:4, 449-456
8
Carmen Andreescu, Charles F. Reynolds. (2012) Depresión a una edad avanzada: tratamiento basado en la evidencia y nuevos caminos prometedores para la investigación y la práctica clínica. Psiquiatría Biológica 19:4, 116-126
9
Cássio M. C. Bottino, Ricardo Barcelos-Ferreira, Salma R. I. Ribeiz. (2012) Treatment of Depression in Older Adults. Current Psychiatry Reports 14:4, 289-297
10
Jane R. Mort, Kristen E. Remund, Bridget Bradley. (2012) Managing Depression for Residents in Nursing Facilities. The Consultant Pharmacist 27:7, 494-503
11
Pim Cuijpers, Annemieke van Straten, Ellen Driessen, Patricia van Oppen, Claudi Bockting, Gerhard Andersson. Depression and Dysthymic Disorders. In: Handbook of Evidence-Based Practice in Clinical Psychology. John Wiley & Sons, Inc., 2012.
12
Ulrich Hegerl, Antje-Kathrin Allgaier, Verena Henkel, Roland Mergl. (2012) Can effects of antidepressants in patients with mild depression be considered as clinically significant?. Journal of Affective Disorders 138:3, 183-191
13
Susan L. Lakey, Andrea Z. LaCroix, Shelly L. Gray, Soo Borson, Carla D. Williams, Darren Calhoun, Joseph S. Goveas, Jordan W. Smoller, Judith K. Ockene, Kamal H. Masaki, Mace Coday, Milagros C. Rosal, Nancy F. Woods. (2012) Antidepressant Use, Depressive Symptoms, and Incident Frailty in Women Aged 65 and Older from the Women's Health Initiative Observational Study. Journal of the American Geriatrics Societyn/a-n/a
14
Carlos Rojas-Fernandez, Mina Mikhail. (2012) Contemporary concepts in the pharmacotherapy of depression in older people. Canadian Pharmacists Journal 145:3, 128-135.e2
15
Rob M. Kok, Willem A. Nolen, Thea J. Heeren. (2012) Efficacy of treatment in older depressed patients: A systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. Journal of Affective Disorders
16
Kathleen L. Patusky, Barbara Caldwell, David Unkle, Bruce Ruck. (2012) Incorporating the Treatment of Medical and Psychiatric Disorders in the Critical Care Area. Critical Care Nursing Clinics of North America 24:1, 53-80
17
Ariel G Gildengers, Meryl A Butters, Denise Chisholm, Stewart J Anderson, Amy Begley, Margo Holm, Joan C Rogers, Charles F Reynolds, Benoit H Mulsant. (2012) Cognition in older adults with bipolar disorder versus major depressive disorder. Bipolar Disorders 14:2, 198-205
18
Namkee G. Choi, Martha L. Bruce, Leslie Sirrianni, Mary Lynn Marinucci, Mark E. Kunik. (2012) Self-reported antidepressant use among depressed, low-income homebound older adults: class, type, correlates, and perceived effectiveness. Brain and Behaviorno-no
19
Rif S. El-Mallakh, Brian Briscoe. (2012) Studies of Long-Term Use of Antidepressants. CNS Drugs 26:2, 97-109
20
Ulrich Hegerl, Peter Schönknecht, Roland Mergl. (2012) Are antidepressants useful in the treatment of minor depression. Current Opinion in Psychiatry 25:1, 1-6
21
E. Schramm, M. Gerardi, B. Rothbaum, M. Berger. Role of psychotherapy in the management of psychiatric diseases. Elsevier, 2012:633-641.
22
Ulrich Hegerl, Paul Holtzheimer, Roland Mergl, William Mcdonald. The neurobiology and treatment of late-life depression. Elsevier, 2012:265-278.
23
Shadi Beshai, Keith S. Dobson, Claudi L.H. Bockting, Leanne Quigley. (2011) Relapse and recurrence prevention in depression: Current research and future prospects. Clinical Psychology Review 31:8, 1349-1360
24
Paola Rucci, Ellen Frank, Simona Calugi, Mario Miniati, Antonella Benvenuti, Meredith Wallace, Andrea Fagiolini, Luca Maggi, David J. Kupfer, Giovanni B. Cassano. (2011) Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. Depression and Anxiety 28:11, 955-962
25
Lacey Gunter, Ji Zhu, Susan Murphy. (2011) Variable Selection for Qualitative Interactions in Personalized Medicine While Controlling the Family-Wise Error Rate. Journal of Biopharmaceutical Statistics 21:6, 1063-1078
26
H.-J. Möller, I. Bitter, J. Bobes, K. Fountoulakis, C. Höschl, S. Kasper. (2011) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry
27
Ruth McCaffrey, Patricia Liehr, Thomas Gregersen, Reiko Nishioka. (2011) Garden Walking and Art Therapy for Depression in Older Adults: A Pilot Study. Research in Gerontological Nursing 4:4, 237-242
28
Minjie Wu, Carmen Andreescu, Meryl A. Butters, Robert Tamburo, Charles F. Reynolds, Howard Aizenstein. (2011) Default-mode network connectivity and white matter burden in late-life depression. Psychiatry Research: Neuroimaging 194:1, 39-46
29
John F. Greden. (2011) The National Network of Depression Centers: progress through partnership. Depression and Anxiety 28:8, 615-621
30
Carmen Andreescu, Charles F. Reynolds. (2011) Late-life Depression: Evidence-based Treatment and Promising New Directions for Research and Clinical Practice. Psychiatric Clinics of North America 34:2, 335-355
31
Dorothy Gaboda, Judith Lucas, Michele Siegel, Ece Kalay, Stephen Crystal. (2011) No Longer Undertreated? Depression Diagnosis and Antidepressant Therapy in Elderly Long-Stay Nursing Home Residents, 1999 to 2007. Journal of the American Geriatrics Society 59:4, 673-680
32
Eric J. Lenze. (2011) Treating Depression in Older Adults with Dementia. Journal of the American Geriatrics Society 59:4, 754-755
33
Fawzi Hindi, Mary Amanda Dew, Steven M. Albert, Francis E. Lotrich, Charles F. Reynolds III. (2011) Preventing Depression in Later Life: State of the Art and Science Circa 2011. Psychiatric Clinics of North America 34:1, 67-78
34
Meredith L. Wallace, Alexandre Y. Dombrovski, Jennifer Q. Morse, Patricia R. Houck, Ellen Frank, George S. Alexopoulos, Charles F. Reynolds, Richard Schulz. (2011) Coping with health stresses and remission from late-life depression in primary care: a two-year prospective study. International Journal of Geriatric Psychiatryn/a-n/a
35
Rob M. Kok, Thea J. Heeren, Willem A. Nolen. (2011) Continuing Treatment of Depression in the Elderly: A Systematic Review and Meta-Analysis of Double-Blinded Randomized Controlled Trials With Antidepressants. The American Journal of Geriatric Psychiatry 19:3, 249-255
36
J. Guidi, G. A. Fava, M. Fava, G. I. Papakostas. (2011) Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychological Medicine 41:02, 321-331
37
Armin R. Azar, Mohit P. Chopra, Lydia Y. Cho, Eugenie Coakley, James L. Rudolph. (2011) Remission in major depression: results from a geriatric primary care population. International Journal of Geriatric Psychiatry 26:1, 48-55
38
Philip Wilkinson. Psychotherapy of Depression and Dysthymia. In: Principles and Practice of Geriatric Psychiatry. John Wiley & Sons, Ltd, 2010:543-551.
39
Mohammed T. Abou-Saleh, Cornelius Katona. Pharmacological Treatment of Depression. In: Principles and Practice of Geriatric Psychiatry. John Wiley & Sons, Ltd, 2010:537-542.
40
Kyaien O. Conner, Brenda Lee, Vanessa Mayers, Deborah Robinson, Charles F. Reynolds, Steve Albert, Charlotte Brown. (2010) Attitudes and beliefs about mental health among African American older adults suffering from depression. Journal of Aging Studies 24:4, 266-277
41
P. Nuss. (2010) Stratégie thérapeutique des épisodes dépressifs. Prévention du risque de récidive. L'Encéphale 36, S145-S149
42
Vahid Payman. (2010) An outpatient psychotherapy clinic for the elderly: Rationale, establishment and characteristics. Asia-Pacific Psychiatry 2:4, 191-200
43
M. Benoit. (2010) Récurrence dépressive chez la personne âgée : quel pronostic cognitif ?. L'Encéphale 36, S132-S135
44
Charles F. Reynolds, Mary Amanda Dew, Lynn M. Martire, Mark D. Miller, Jill M. Cyranowski, Eric Lenze, Ellen M. Whyte, Benoit H. Mulsant, Bruce G. Pollock, Jordan F. Karp, Ariel Gildengers, Katalin Szanto, Alexandre Y. Dombrovski, Carmen Andreescu, Meryl A. Butters, Jennifer Q. Morse, Patricia R. Houck, Salem Bensasi, Sati Mazumdar, Jacqueline A. Stack, Ellen Frank. (2010) Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. International Journal of Geriatric Psychiatry 25:11, 1134-1141
45
Steven D. Hollon, Kathryn Ponniah. (2010) A review of empirically supported psychological therapies for mood disorders in adults. Depression and Anxiety 27:10, 891-932
46
F. Veiga Fernández. (2010) Alteraciones psiquiátricas en geriatría. Medicine - Programa de Formación Médica Continuada Acreditado 10:62, 4263-4271
47
Carlos H. Rojas-Fernandez, Lisa J. Miller, Cheryl A. Sadowski. (2010) Considerations in the Treatment of Geriatric Depression. Research in Gerontological Nursing 3:3, 176-186
48
Kyaien O. Conner, Valire Carr Copeland, Nancy K. Grote, Gary Koeske, Daniel Rosen, Charles F. Reynolds, Charlotte Brown. (2010) Mental Health Treatment Seeking Among Older Adults With Depression: The Impact of Stigma and Race. The American Journal of Geriatric Psychiatry 18:6, 531-543
49
Charles F. Reynolds. (2009) Prevention of depressive disorders: a brave new world. Depression and Anxiety 26:12, 1062-1065
50
Depression and anxiety. In: The Maudsley Prescribing Guidelines, Tenth Edition. CRC Press, 2009:155-250.
51
Joel Sadavoy. (2009) An integrated model for defining the scope of psychogeriatrics: the five Cs. International Psychogeriatrics 21:05, 805
52
Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten, Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, S26-S43
53
Gregory A. Hinrichsen. (2009) Interpersonal Psychotherapy: A Treatment for Late-Life Depression. Psychiatric Annals 39:9, 838-843
54
Carmen Andreescu, Meryl Butters, Eric J. Lenze, Vijay K. Venkatraman, Megan Nable, Charles F. Reynolds, Howard J. Aizenstein. (2009) fMRI activation in late-life anxious depression: a potential biomarker. International Journal of Geriatric Psychiatry 24:8, 820-828
55
Michael E. Thase, Aaron M. Koenig. Outcomes in the Treatment of Major Depressive Disorder. Informa Healthcare, 2009:22-53.
56
Robert G. Robinson, Veselin Tenev, Ricardo E. Jorge. (2009) Citalopram for Continuation Therapy After Repetitive Transcranial Magnetic Stimulation in Vascular Depression. The American Journal of Geriatric Psychiatry 17:8, 682-687
57
Lea C. Watson, Sheryl Zimmerman, Lauren W. Cohen, Rosalie Dominik. (2009) Practical Depression Screening in Residential Care/Assisted Living: Five Methods Compared With Gold Standard Diagnoses. The American Journal of Geriatric Psychiatry 17:7, 556-564
58
Philip Wilkinson. (2009) Cognitive behavioural therapy with older adults: enthusiasm without the evidence?. The Cognitive Behaviour Therapist 2:02, 75
59
T. Gallarda, H. Lôo. (2009) Dépression et personnes âgées. L'Encéphale 35:3, 269-280
60
David B. Bekelman, John S. Rumsfeld, Edward P. Havranek, Traci E. Yamashita, Evelyn Hutt, Sheldon H. Gottlieb, Sydney M. Dy, Jean S. Kutner. (2009) Symptom Burden, Depression, and Spiritual Well-Being: A Comparison of Heart Failure and Advanced Cancer Patients. Journal of General Internal Medicine 24:5, 592-598
61
G. S. Malhi, D. Adams, R. Porter, A. Wignall, L. Lampe, N. O’Connor, M. Paton, L. A. Newton, G. Walter, A. Taylor, M. Berk, R. T. Mulder. (2009) Clinical practice recommendations for depression. Acta Psychiatrica Scandinavica 119, 8-26
62
Yuhua Bao, Edward P. Post, Thomas R. Ten Have, Bruce R. Schackman, Martha L. Bruce. (2009) Achieving Effective Antidepressant Pharmacotherapy in Primary Care: The Role of Depression Care Management in Treating Late-Life Depression. Journal of the American Geriatrics Society 57:5, 895-900
63
Alex Cohen, Stephen E. Gilman, Patricia R. Houck, Katalin Szanto, Charles F. Reynolds. (2009) Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults. Social Psychiatry and Psychiatric Epidemiology 44:4, 272-277
64
Carmen Andreescu, Eric J. Lenze, Benoit H. Mulsant, Julie Loebach Wetherell, Amy E. Begley, Sati Mazumdar, Charles F. Reynolds. (2009) High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depression and Anxiety 26:3, 266-272
65
Ching-Yen Chen, Chia-Yih Liu, Hsin-Yi Liang. (2009) Comparison of patient and caregiver assessments of depressive symptoms in elderly patients with depression. Psychiatry Research 166:1, 69-75
66
Jordan F. Karp, Debra K. Weiner, Mary A. Dew, Amy Begley, Mark D. Miller, Charles F. Reynolds. (2009) Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study. International Journal of Geriatric Psychiatryn/a-n/a
67
Philip Wilkinson, Nicola Alder, Edmund Juszczak, Helen Matthews, Claire Merritt, Harriet Montgomery, Robert Howard, Alastair Macdonald, Robin Jacoby. (2009) A pilot randomised controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depression. International Journal of Geriatric Psychiatry 24:1, 68-75
68
BG Pollock, CE Forsyth, RR Bies. (2009) The Critical Role of Clinical Pharmacology in Geriatric Psychopharmacology. Clinical Pharmacology & Therapeutics 85:1, 89-93
69
Tarek K. Rajji, Dielle Miranda, Benoit H. Mulsant, Meredith Lotz, Patricia Houck, Michelle D. Zmuda, Salem Bensasi, Charles F. Reynolds, Meryl A. Butters. (2009) The MMSE is not an adequate screening cognitive instrument in studies of late-life depression. Journal of Psychiatric Research 43:4, 464-470
70
Psychological medicine. In: Kumar and Clark's Clinical Medicine. Elsevier, 2009:1185-1223.
71
John J. Haggerty, Micah J. Sickel. Depression. In: Netter's Internal Medicine. Elsevier, 2009:1163-1167.
72
Zeina Chemali, Lama M. Chahine, Gregory Fricchione. (2009) The Use of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Harvard Review of Psychiatry 17:4, 242-253
73
Howard J. Aizenstein, Meryl A. Butters, Minjie Wu, Laura M. Mazurkewicz, V Andrew Stenger, Peter J. Gianaros, James T. Becker, Charles F. Reynolds, Cameron S. Carter. (2009) Altered Functioning of the Executive Control Circuit in Late-Life Depression: Episodic and Persistent Phenomena. The American Journal of Geriatric Psychiatry 17:1, 30-42
74
Gregory A. Hinrichsen. (2008) Interpersonal Psychotherapy for Late Life Depression: Current Status and New Applications. Journal of Rational-Emotive & Cognitive-Behavior Therapy 26:4, 263-275
75
Julie A Kmiec, Ariel Gildengers, Robert C Young, Charles F Reynolds. Late-Life Depression and Bipolar Disorder: Factors Affecting Long-Term Prognosis and Maintenance Treatment Outcomes. Informa Healthcare, 2008:347-362.
76
Kristen Carreira, Mark D. Miller, Ellen Frank, Patricia R. Houck, Jennifer Q. Morse, Mary Amanda Dew, Meryl A. Butters', Charles F. Reynolds. (2008) A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function. International Journal of Geriatric Psychiatry 23:11, 1110-1113
77
Carmen Andreescu, Meryl A Butters, Amy Begley, Tarek Rajji, Minjie Wu, Carolyn C Meltzer, Charles F Reynolds, Howard Aizenstein. (2008) Gray Matter Changes in Late Life Depression—a Structural MRI Analysis. Neuropsychopharmacology 33:11, 2566-2572
78
Jules Rosen, Benoit H. Mulsant, Patricia Marino, Christopher Groening, Robert C. Young, Debra Fox. (2008) Web-based training and interrater reliability testing for scoring the Hamilton Depression Rating Scale. Psychiatry Research 161:1, 126-130
79
Hans-Jürgen Möller, David S. Baldwin, Guy Goodwin, Siegfried Kasper, Ahmed Okasha, Dan J. Stein, Rajiv Tandon, Marcio Versiani, . (2008) Do SSRIs or antidepressants in general increase suicidality?. European Archives of Psychiatry and Clinical Neuroscience 258:S3, 3-23
80
Amy Cheung, Vivek Kusumakar, Stan Kutcher, Elyse Dubo, Jane Garland, Margaret Weiss, Alex Kiss, Anthony Levitt. (2008) Maintenance Study for Adolescent Depression. Journal of Child and Adolescent Psychopharmacology 18:4, 389-394
81
Sandor Kalmar, Katalin Szanto, Zoltan Rihmer, Sati Mazumdar, Katrin Harrison, J. John Mann. (2008) Antidepressant Prescription and Suicide Rates: Effect of Age and Gender. Suicide and Life-Threatening Behavior 38:4, 363-374
82
Bi Rong Dong, Ping He, Zhenchan Lu, Taixiang Wu, Guan Jian Liu, Chang Quan Huang, Chang Quan Huang. Exercise for older depressed people. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008.
83
P.-O. Lang, Y. Hasso, H. Hilleret, N. Vogt-Ferrier. (2008) Syndrome sérotoninergique consécutif à l’association d’escitalopram et de cyclosporine chez une patiente de 84 ans. La Revue de Médecine Interne 29:7, 583-586
84
J Craig Nelson, Kevin Delucchi, Lon S. Schneider. (2008) Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence. The American Journal of Geriatric Psychiatry 16:7, 558-567
85
Charles F. Reynolds. (2008) Preventing Depression in Old Age: It's Time. The American Journal of Geriatric Psychiatry 16:6, 433-434
86
&NA;. (2008) Persistence is the key to treating nonpsychotic major depressive disorder in elderly patients. Drugs & Therapy Perspectives 24:5, 17-20
87
Susan G Kornstein. (2008) Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study. Expert Review of Neurotherapeutics 8:5, 737-742
88
C. Katona. (2008) New Antidepressants for Older People: A Critical Review of the Evidence Base. L'Encéphale 34, S71-S76
89
Ariel G. Gildengers, Ellen M. Whyte, Rebecca A. Drayer, Isabella Soreca, Andrea Fagiolini, Amy M. Kilbourne, Patricia R. Houck, Charles F. Reynolds, Ellen Frank, David J. Kupfer, Benoit H. Mulsant. (2008) Medical Burden in Late-Life Bipolar and Major Depressive Disorders. The American Journal of Geriatric Psychiatry 16:3, 194-200
90
Mark D. Miller. (2008) Using interpersonal therapy (IPT) with older adults today and tomorrow: A review of the literature and new developments. Current Psychiatry Reports 10:1, 16-22
91
Alexandre Y. Dombrovski, Meryl A. Butters, Charles F. Reynolds, Patricia R. Houck, Luke Clark, Sati Mazumdar, Katalin Szanto. (2008) Cognitive Performance in Suicidal Depressed Elderly: Preliminary Report. The American Journal of Geriatric Psychiatry 16:2, 109-115
92
Matthias Backenstrass, Christoph Mundt. Affektive Störungen. In: Störungsorientierte Psychotherapie. Elsevier, 2008:371-411.
93
Petra Dykierek. Psychotherapie mit alten Menschen. In: Störungsorientierte Psychotherapie. Elsevier, 2008:597-608.
94
Tarek K Rajji, Benoit H Mulsant, Francis E Lotrich, Cynthia Lokker, Charles F Reynolds. (2008) Use of Antidepressants in Late-Life Depression. Drugs & Aging 25:10, 841-853
95
Helen Lavretsky, Prabha Siddarth, Anand Kumar, Charles F. Reynolds. (2008) The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. International Journal of Geriatric Psychiatry 23:1, 55-59
96
Pascal Odou, Hugues Robert, Bertrand Decaudin. Traitement de la dépression. In: Pharmacie clinique et thérapeutique. Elsevier, 2008:859-882.
97
M. Cornelia Cremens. Geriatric Psychiatry. In: Massachusetts General Hospital Comprehensive Clinical Psychiatry. Elsevier, 2008:963-971.
98
George S. Alexopoulos, Carla M. Canuso, Georges M. Gharabawi, Cynthia A. Bossie, Andrew Greenspan, Ibrahim Turkoz, Charles Reynolds. (2008) Placebo-Controlled Study of Relapse Prevention With Risperidone Augmentation in Older Patients with Resistant Depression. The American Journal of Geriatric Psychiatry 16:1, 21-30
99
Corrine I. Voils, Jason C. Allaire, Maren K. Olsen, David C. Steffens, Rick H. Hoyle, Hayden B. Bosworth. (2007) Five-year trajectories of social networks and social support in older adults with major depression. International Psychogeriatrics 19:06,
100
Charles F. Reynolds, Mario Cruz, Carrie Farmer Teh, Bruce L. Rollman. (2007) Improving Evidence-Based Management of Depression for Older Americans in Primary Care: If Not Now, When?. Journal of the American Geriatrics Society 55:12, 2083-2085
101
Unützer , Jürgen , . (2007) Late-Life Depression. New England Journal of Medicine 357:22, 2269-2276
Full Text102
Alexandre Y. Dombrovski, Benoit H. Mulsant, Patricia R. Houck, Sati Mazumdar, Eric J. Lenze, Carmen Andreescu, Jill M. Cyranowski, Charles F. Reynolds. (2007) Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders 103:1-3, 77-82
103
Psychotherapies, alone and in combination. In: Treating Depression Effectively. CRC Press, 2007:29-48.
104
Depression in late life. In: Treating Depression Effectively. CRC Press, 2007:155-165.
105
David B. Bekelman, Edward P. Havranek, Diane M. Becker, Jean S. Kutner, Pamela N. Peterson, Ilan S. Wittstein, Sheldon H. Gottlieb, Traci E. Yamashita, Diane L. Fairclough, Sydney M. Dy. (2007) Symptoms, Depression, and Quality of Life in Patients With Heart Failure. Journal of Cardiac Failure 13:8, 643-648
106
Gene A. Nakajima, Neil S. Wenger. (2007) Quality Indicators for the Care of Depression in Vulnerable Elders. Journal of the American Geriatrics Society 55, S302-S311
107
Barbara J Zarowitz. (2007) Limits of evidence-based medicine in older adults. Aging Health 3:5, 601-610
108
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, 421-433
109
Alexandre Y. Dombrovski, Eric J. Lenze, Mary Amanda Dew, Benoit H. Mulsant, Bruce G. Pollock, Patricia R. Houck, Charles F. Reynolds. (2007) Maintenance Treatment for Old-Age Depression Preserves Health-Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy. Journal of the American Geriatrics Society 55:9, 1325-1332
110
Melina Siamouli, Stamatia Magiria, Panagiotis Panagiotidis, Styliani Spyridi, Stavroula Sokolaki, Konstantinos N Fountoulakis, George Kaprinis. (2007) Advances in the treatment of geriatric depression. Aging Health 3:4, 495-507
111
Philip Gorwood, Emmanuelle Weiller, Ole Lemming, Cornelius Katona. (2007) Escitalopram Prevents Relapse in Older Patients With Major Depressive Disorder. The American Journal of Geriatric Psychiatry 15:7, 581-593
112
Barnett S. Meyers. (2007) Optimizing the Use of Data Generated by Geriatric Depression Treatment Studies During a Time of Diminishing Resources. The American Journal of Geriatric Psychiatry 15:7, 545-552
113
Leslie Hasche, Nancy Morrow-Howell. Depression. In: Handbook of Gerontology. John Wiley & Sons, Inc., 2007:269-308.
114
Barbara J. Zarowitz. (2007) Antidepressant Tapering: Avoiding Adverse Consequences of Gradual Dose Reduction. Geriatric Nursing 28:2, 75-79
115
Katalin Szanto, Benoit H. Mulsant, Patricia R. Houck, Mary Amanda Dew, Alexandre Dombrovski, Bruce G. Pollock, Charles F. Reynolds. (2007) Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. Journal of Affective Disorders 98:1-2, 153-161
116
Chi-Un Pae, Ashwin A Patkar. (2007) Paroxetine: current status in psychiatry. Expert Review of Neurotherapeutics 7:2, 107-120
117
Henry C Driscoll, Jordan F Karp, Mary Amanda Dew, Charles F Reynolds. (2007) Getting Better, Getting Well. Drugs & Aging 24:10, 801-814
118
Frederic C. Blow, Laurie M. Brockmann, Kristen L. Barry. Relapse Prevention with Older Adults. In: Therapist's Guide to Evidence-Based Relapse Prevention. Elsevier, 2007:313-337.
119
Warren D. Taylor, David C. Steffens, K. Ranga Krishnan. (2006) Psychiatric Disease in the Twenty-First Century: The Case for Subcortical Ischemic Depression. Biological Psychiatry 60:12, 1299-1303
120
Hans-Jürgen Möller. (2006) Is there evidence for negative effects of antidepressants on suicidality in depressive patients?. European Archives of Psychiatry and Clinical Neuroscience 256:8, 476-496
121
Emma Teper, Alan Thomas. (2006) Is depression different in older adults?. Aging Health 2:6, 905-915
122
Kristin L. Bigos, Robert R. Bies, Bruce G. Pollock. (2006) Population Pharmacokinetics in Geriatric Psychiatry. The American Journal of Geriatric Psychiatry 14:12, 993-1003
123
Susan W. Lehmann, Peter V. Rabins. (2006) Factors related to hospitalization in elderly manic patients with early and late-onset bipolar disorder. International Journal of Geriatric Psychiatry 21:11, 1060-1064
124
(2006) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 21:10, 1005-1012
125
(2006) Maintenance Treatment of Depression in Old Age. New England Journal of Medicine 354:23, 2505-2506
Free Full Text126
. (2006) De duur van onderhoudsbehandeling met antidepressiva bij ouderen. Huisarts en Wetenschap 49:6, 468-469
127
Reifler , Burton V. , . (2006) Play It Again, Sam — Depression Is Recurring. New England Journal of Medicine 354:11, 1189-1190
Full Text
- Letters
